ICCC vs MYGN: stock comparison and AI forecast
Immucell Corp /De/ (ICCC) and Myriad Genetics Inc (MYGN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ICCC Immucell Corp /De/
- Price
- $9.95 +17.5% · 6M
- Market Cap
- $90M
- P/E Ratio
- 497.6x
- Size
- small-cap
- AI Forecast
MYGN Myriad Genetics Inc
- Market Cap
- $566M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- MYGN is 6.3 times larger than ICCC by market capitalization ($566M against $90M).
- MYGN carries 1.26 times debt per unit of equity, against 0.49 times for ICCC.
- Both companies share the SEC industry classification In Vitro & In Vivo Diagnostic Substances.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ICCC | MYGN |
|---|---|---|
| Market Cap | $90M | $566M |
| P/E Ratio | 497.63x | – |
| P/B Ratio | 2.88x | 2.11x |
| EPS | $0.02 | $-4.58 |
| Book Value/Share | $3.45 | $2.81 |
| Revenue/Share | $3.38 | $8.40 |
| FCF/Share | $0.46 | – |
Profitability & Margins
| Metric | ICCC | MYGN |
|---|---|---|
| ROE | 2.5% | – |
| ROA | 1.7% | – |
| ROIC | 9.2% | -24.4% |
| Gross Margin | 40.3% | 68.3% |
| Operating Margin | 12.6% | -14.3% |
| Net Margin | 2.6% | – |
| EBT Margin | 2.8% | -16.1% |
| Tax Rate | 7.8% | 0.1% |
Financial Health
| Metric | ICCC | MYGN |
|---|---|---|
| Current Ratio | 4.75x | 1.98x |
| Quick Ratio | 2.71x | 1.77x |
| D/E Ratio | 0.49x | 1.26x |
| Financial Leverage | 1.49x | 2.26x |
| Interest Coverage | 20.4x | -11.7x |
| Working Capital | $17M | $134M |
Cash Flow
| Metric | ICCC | MYGN |
|---|---|---|
| Operating Cash Flow | $6M | -$14M |
| Free Cash Flow | $4M | – |
| Capital Spending | -$2M | – |
| OCF Growth YoY | 132.6% | – |
| FCF Growth YoY | 138.9% | – |
| FCF/Sales | 13.7% | – |
| CapEx/Sales | 5.5% | – |
Operational Efficiency
| Metric | ICCC | MYGN |
|---|---|---|
| Asset Turnover | 0.66x | 1.32x |
| Receivables Turnover | 10.6x | 7.6x |
| Inventory Turnover | 2.0x | 8.9x |
| Fixed Assets Turnover | 1.5x | 7.7x |
| Days Sales Outstanding | 34 days | 48 days |
| Days Inventory | 181 days | 41 days |
| Payables Period | 56 days | 40 days |
| Cash Conversion Cycle | 159 days | 49 days |
Income Statement
| Metric | ICCC | MYGN |
|---|---|---|
| Total Revenue | $31M | $804M |
| Operating Income | $4M | -$115M |
| Net Income | $790K | – |
| R&D Expense | $2M | $104M |
| SG&A Expense | $10M | $604M |
| Cost of Goods Sold | $18M | $254M |
Dividend & Shareholder Information
| Metric | ICCC | MYGN |
|---|---|---|
| Shares Outstanding | 9M | 96M |
| Net Income Growth | -40.5% | – |
ICCC vs MYGN: stock comparison and AI forecast
Which is bigger, ICCC or MYGN?
MYGN is 6.3 times larger than ICCC by market capitalization ($566M against $90M).
Which one does Intratio's AI model rank higher, ICCC or MYGN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.